%0 Journal Article %A Ankita Srivastava %A Vandana Tamrakar %A Moradhvaj %A Saddaf Naaz Akhtar %A Krishna Kumar %A Tek Chand Saini %A C Nagendra %A Nandita Saikia %T Geographical Variation in COVID-19 Cases, Prevalence, Recovery and Fatality Rate by Phase of National Lockdown in India, March 14-May 29, 2020 %D 2020 %R 10.1101/2020.06.04.20122028 %J medRxiv %P 2020.06.04.20122028 %X Background Since the COVID-19 pandemic hit Indian states at varying speed, it is crucial to investigate the geographical pattern in COVID-19. We analyzed the geographical pattern of COVID-19 prevalence and mortality by the phase of national lockdown in India.Method Using publicly available compiled data on COVID-19, we estimated the trends in new cases, period-prevalence rate (PPR), case recovery rate (CRR), and case fatality ratio (CFR) at national, state and district level.Findings The age and sex are missing for more than 60 percent of the COVID-19 patients. There is an exponential increase in COVID-19 cases both at national and sub-national levels. The COVID-19 infected has jumped about 235 times (from 567 cases in the pre-lockdown period to 1,33,669 in the fourth lockdown); the average daily new cases have increased from 57 in the first lockdown to 6,482 in the fourth lockdown; the average daily recovered persons from 4 to 3,819; the average daily death from 1 to 163. From first to the third lockdown, PPR (0.04 to 5.94), CRR (7.05 to 30.35) and CFR (1.76 to 1.89) have consistently escalated. At state-level, the maximum number of COVID-19 cases is found in the states of Maharashtra, Tamil Nadu, Delhi, and Gujarat contributing 66.75 percent of total cases. Whereas no cases found in some states, Kerela is the only state flattening the COVID-19 curve. The PPR is found to be highest in Delhi, followed by Maharastra. The highest recovery rate is observed in Kerala, till second lockdown; and in Andhra Pradesh in third lockdown. The highest case fatality ratio in the fourth lockdown is observed in Gujarat and Telangana. A few districts viz. like Mumbai (96.7); Chennai (63.66) and Ahmedabad (62.04) have the highest infection rate per 100 thousand population. Spatial analysis shows that clusters in Konkan coast especially in Maharashtra (Palghar, Mumbai, Thane and Pune); southern part from Tamil Nadu (Chennai, Chengalpattu and Thiruvallur), and the northern part of Jammu & Kashmir (Anantnag, Kulgam) are hot-spots for COVID-19 infection while central, northern and north-eastern regions of India are the cold-spots.Conclusion India has been experiencing a rapid increase of COVID-19 cases since the second lockdown phase. There is huge geographical variation in COVID-19 pandemic with a concentration in some major cities and states while disaggregated data at local levels allows understanding geographical disparity of the pandemic, the lack of age-sex information of the COVID-19 patients forbids to investigate the individual pattern of COVID-19 burden.Major highlights of the studyThe new cases of COVID-19 have increased exponentially since the second lockdown phase in India. There is consistent improvement in the recovery rate (CRR is 7.1 percent in pre-lockdown to 44.0 percent in fourth lockdown period) with a low level of CFR (1.87 percent as of May 29st 2020).At the state level, the most vulnerable states for the COVID-19 crisis are the state of Maharashtra, Tamil Nadu, Delhi, and Gujarat contributing 66.75 percent of total cases.The PPR is found to be highest in Delhi, followed by Maharastra. While the highest recovery rate is observed in Kerala, the highest case fatality ratio in the fourth lockdown is observed in Gujarat and Telangana. The top 10 hotspot districts in India account for 58.3 percent of the new cases. Among them, Mumbai has the highest infection rate of 96.77 per 100 thousand, followed by Chennai with 63.66 per 100 thousand, and Ahmedabad with 62.04 per 100 thousand.The information on age and sex are missing for more than 60 percent of the patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data is publicly availableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe used publicly available data from https://www.covid19india.org/. It is an Application Programming Interface (API) for daily monitoring of the COVID-19 cases at national, state, and district levels. https://www.covid19india.org/ %U https://www.medrxiv.org/content/medrxiv/early/2020/06/05/2020.06.04.20122028.full.pdf